
|Articles|October 23, 2014
US Healthcare Reform: A Pharm Exec Digest Special
Author(s)The Pharm Exec staff
This month’s special issue of Pharm Exec Global Digest looks at..
Advertisement
This month’s special issue of Pharm Exec Global Digest looks at
- Dealing with the “side effects” of Obamacare
- The “value” of Rxs under Obamacare
- The escalating cost of US oncology care
- And more…
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
AstraZeneca Reaches $2 Billion License Agreement with Jacobio Pharma for Pan-KRAS Inhibitor
2
JP Morgan 2026 Preview: Eli Lilly Seeks Bounce Back
3
Alnylam Announces $250 Million Investment in Massachusetts Facility
4
Pharmaceutical Executive Daily: Nine New Additions to TrumpRx
5




